Predictive Value of FOLFOX-Based Regimen, Long Interval, Hemoglobin Levels and Clinical Negative Nodal Status, and Postchemoradiotherapy CEA Levels for Pathological Complete Response in Patients with Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy

Table 2

Independent clinical parameters significantly associated with a pCR.

Parameter	OR	95% CI	value
Chemotherapy (FOLFOX vs. non-FOLFOX)	5.385	1.699–17.688	0.0044
Clinical N stage (N0 vs. N1/2)	3.200	1.279–8.410	0.0135
Anemia during CRT (Hb > 10 vs. Hb≤ 10)	3.067	1.251–8.187	0.0125
Post-CRT CEA (≤2 vs. > 2)	2.891	1.156–7.369	0.0233
RT to surgery interval (>8 weeks vs. ≤8 weeks)	1.135	1.021–5.712	0.0469
Gender (male vs. female)	0.607	0.291–1.265	0.1823
Age (≤60 vs. > 60)	0.680	0.329–1.265	0.2850
Location of tumor (middle/low vs. upper)	1.895	0.911–4.068	0.0877
Grade (WD/MD vs. PD)	0.349	0.064–2.113	0.2373
Clinical T stage (T2/3 vs. T4)	1.810	0.615–6.186	0.2907
Radiation dose (<5000 vs. ≥ 5000)	0.626	0.186–1.799	0.3972
Pre-CRT CEA (≤5 vs. > 5)	1.761	0.861–3.727	0.1221
Leukopenia during CRT(WBC>3000 vs. WBC≤3000)	0.833	0.378–1.826	0.6479
Cycles of pre-OP chemotherapy(≥7 vs. < 7)	1.037	0.656–1.625	0.8732
ycT stage (T0-2 vs. T3-4)	1.872	0.886–4.110	0.1008
ycN stage (N0 vs. N1/2)	1.624	0.799–3.311	0.1788

CEA, carcinoembryonic antigen; CRT, chemoradiation therapy; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; Hb, hemoglobin; OP, operative; pCR, pathological complete response; RT, radiation therapy; WBC, white blood cell; ycT stage: clinical tumor stage after chemoradiotherapy; ycN stage: clinical nodal stage after chemoradiotherapy. Logistic regression.